| 000 | 01752 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516082246.0 | ||
| 264 | 0 | _c20121226 | |
| 008 | 201212s 0 0 eng d | ||
| 022 | _a1432-1041 | ||
| 024 | 7 |
_a10.1007/s00228-012-1248-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHelldén, A | |
| 245 | 0 | 0 |
_aThe dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cSep 2012 |
||
| 300 |
_a1281-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2D6 _xmetabolism |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2D6 Inhibitors |
| 650 | 0 | 4 | _aDealkylation |
| 650 | 0 | 4 |
_aDopamine Antagonists _xadministration & dosage |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 | _aGlomerular Filtration Rate |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntestinal Absorption |
| 650 | 0 | 4 |
_aKidney _xmetabolism |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aPiperidines _xadministration & dosage |
| 650 | 0 | 4 | _aSweden |
| 650 | 0 | 4 | _aWhite People |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aPanagiotidis, G | |
| 700 | 1 | _aJohansson, P | |
| 700 | 1 | _aWaters, N | |
| 700 | 1 | _aWaters, S | |
| 700 | 1 | _aTedroff, J | |
| 700 | 1 | _aBertilsson, L | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 68 _gno. 9 _gp. 1281-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00228-012-1248-z _zAvailable from publisher's website |
| 999 |
_c21604844 _d21604844 |
||